Home   |   Business News   |   Personal Finance   |   World News   |   U.S. News   |   Technology   |   Stock Alert   |   Stock Picks  |   Breaking News  |   Forex  |   Gold
Custom Search

Spectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results

Spectrum Pharmaceuticals Inc. (SPPI) announced Tuesday that the interim data from its Phase 2 clinical study of poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer was presented in Yokohama, Japan.

IBM Corp. (IBM) Has Surged To Over A 5-Month High After Q3 Profit Beat

IBM Corp. (IBM) reported third quarter EPS of $3.30 after the bell Tuesday, compared to $3.29 in the prior year period. Street expectations were for EPS of $3.28.

Unitedhealth Group Inc. (UNH) Has Broken Out To A New High On Q3 Results

Unitedhealth Group Inc. (UNH) reported third quarter EPS of $2.66 Tuesday morning, up from $2.17 last year. The consensus estimate was for EPS of $2.56.

Exelixis Inc. (EXEL) Has Broken Out To A New High On FDA Priority Review

Exelixis Inc. (EXEL) announced Monday morning that its Phase 3 trial of cabozantinib in patients with advanced hepatocellular carcinoma met its primary endpoint.

AnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study Results

AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.

Constellation Brands Inc. (STZ) Has Jumped To A New High On Strong Q2 Results

Constellation Brands Inc. (STZ) reported second quarter EPS of $2.47 Thursday morning, up from $1.77 a year ago. Analysts expected EPS of $2.17. The company also increased its full year EPS forecast on a comparable basis to between $8.25 and $8.40, from prior expectations of $7.90 to $8.10. The consensus estimate is for EPS of $8.18.

Zogenix Inc. (ZGNX) Has Soared To A New High On Phase 3 Study Results

Zogenix Inc. (ZGNX) announced Friday morning that its Phase 3 trial of ZX008, for the treatment of Dravet syndrome, met its primary objective and demonstrated statistically significant improvements versus placebo in all key secondary measures.

Tyson Foods Inc. (TSN) Has Jumped To A 10-Month High After Guidance Increase

Tyson Foods Inc. (TSN) announced after the bell Thursday that it now expects to report full year adjusted EPS of $5.20 to $5.30, up from prior expectations of $4.95 to $5.05.
   S & P 500




   Latest News From CNN Money

NFL won't force players to stand during Anthem
Gretchen Carlson: 'The floodgates have opened'
5 ways to improve your credit -- fast
Inequality among America's seniors is getting worse
Trump's perfect pick for Fed chair: Janet Yellen
   Latest News From The Wall Street Journal
Future of Tech and Media: Waging a War for People's Time
  Business News
  Personal Finance
  World News
  U.S. News


                 Copyright , Invest.